Obesity deals come into focus after Roche shells out $2.7B for Carmot
Roche’s $2.7 billion bolt-on deal for Carmot Therapeutics is the latest example of how pharma companies are racing to get back into …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
